Beyond risk prediction, increasing evidence links Cav-3/caveolae to HF-relevant pathophysiology, including arrhythmia susceptibility and insulin-signaling defects in ischemic or metabolic heart disease—both potential treatment targets (5, 24). The gene discussed is INS; the disease is cardiac arrhythmia.